416 related articles for article (PubMed ID: 29614779)
1. Advances in HIV-1 Vaccine Development.
Gao Y; McKay PF; Mann JFS
Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
[TBL] [Abstract][Full Text] [Related]
2. Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.
Stephenson KE; Wagh K; Korber B; Barouch DH
Annu Rev Immunol; 2020 Apr; 38():673-703. PubMed ID: 32340576
[TBL] [Abstract][Full Text] [Related]
3. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
4. Prospects for a globally effective HIV-1 vaccine.
Excler JL; Robb ML; Kim JH
Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
[TBL] [Abstract][Full Text] [Related]
5. First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses.
Choi E; Michalski CJ; Choo SH; Kim GN; Banasikowska E; Lee S; Wu K; An HY; Mills A; Schneider S; Bredeek UF; Coulston DR; Ding S; Finzi A; Tian M; Klein K; Arts EJ; Mann JF; Gao Y; Kang CY
Retrovirology; 2016 Nov; 13(1):82. PubMed ID: 27894306
[TBL] [Abstract][Full Text] [Related]
6. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
[TBL] [Abstract][Full Text] [Related]
7. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
8. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
9. Current views on the potential for development of a HIV vaccine.
Cohen KW; Frahm N
Expert Opin Biol Ther; 2017 Mar; 17(3):295-303. PubMed ID: 28095712
[TBL] [Abstract][Full Text] [Related]
10. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
[TBL] [Abstract][Full Text] [Related]
11. Strategies for eliciting HIV-1 inhibitory antibodies.
Tomaras GD; Haynes BF
Curr Opin HIV AIDS; 2010 Sep; 5(5):421-7. PubMed ID: 20978384
[TBL] [Abstract][Full Text] [Related]
12. No acquisition: a new ambition for HIV vaccine development?
Lakhashe SK; Silvestri G; Ruprecht RM
Curr Opin Virol; 2011 Oct; 1(4):246-53. PubMed ID: 22081778
[TBL] [Abstract][Full Text] [Related]
13. The changing face of HIV vaccine research.
Kwong PD; Mascola JR; Nabel GJ
J Int AIDS Soc; 2012 Jul; 15(2):17407. PubMed ID: 22789610
[TBL] [Abstract][Full Text] [Related]
14. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
15. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
J Virol; 2017 May; 91(9):. PubMed ID: 28202762
[TBL] [Abstract][Full Text] [Related]
16. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
[TBL] [Abstract][Full Text] [Related]
17. A critical question for HIV vaccine development: which antibodies to induce?
Zolla-Pazner S
Science; 2014 Jul; 345(6193):167-8. PubMed ID: 25013066
[TBL] [Abstract][Full Text] [Related]
18. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
[TBL] [Abstract][Full Text] [Related]
19. Development of prophylactic vaccines against HIV-1.
Schiffner T; Sattentau QJ; Dorrell L
Retrovirology; 2013 Jul; 10():72. PubMed ID: 23866844
[TBL] [Abstract][Full Text] [Related]
20. Progress in HIV vaccine development.
Hsu DC; O'Connell RJ
Hum Vaccin Immunother; 2017 May; 13(5):1018-1030. PubMed ID: 28281871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
